KeyBanc Reiterates Overweight Rating on Castle Biosciences (CSTL) as 'TissueCypher Gains Momentum'
Tweet Send to a Friend
KeyBanc analyst Paul Knight reiterated an Overweight rating and $36.00 price target on Castle Biosciences (NASDAQ: CSTL).The analyst commented: "TissueCypher ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
